Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of post-allogeneic hematopoietic stem cell transplantation (HSCT) aGVHD at screening~* Evidence of engraftment post-transplant~* Diagnosis of high-risk aGVHD, per refined Minnesota high-risk aGVHD criteria during screening~* Initiation of treatment with systemic corticosteroids for aGVHD at a dose of prednisone ≥2 milligrams per kilograms per day (mg/kg/day) by orally (PO) or methylprednisolone ≥2 mg/kg/day intravenously (or equivalent) in divided doses at diagnosis and up to 3 days prior to or on the same day as initiation of GDC-8264 (Day 1), with no taper planned prior to Day 3~Exclusion Criteria:~* Evidence of relapsed, progressing, or persistent malignancy, or treatment for relapse after transplant, or requirement for rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse~* Prior receipt of more than one allogeneic HSCT~* Prior receipt of solid organ transplantation that are target organs for aGVHD (e.g., liver transplant)~* Prior systemic treatment for aGVHD, except for the standard of care corticosteroid treatment initiated as part of this trial~* Diagnosis of chronic GVHD or overlap syndrome~* Uncontrolled active infection (i.e., progressive symptoms related to infection despite treatment, or persistently positive blood cultures despite treatment, or any other evidence of severe sepsis)~* Severe organ dysfunction (e.g., acute liver failure, renal failure requiring dialysis, ventilator support, or vasopressor therapy)~* Initiation or planned use of a marketed small molecule (excluding corticosteroids) or biologic therapy as treatment for aGVHD from the start of screening through the treatment period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDC-8264, 35 mg (Type: EXPERIMENTAL): Participants will receive oral GDC-8264, 35 milligrams (mg), once daily (QD) for 28 days.
- GDC-8264, 75 mg (Type: EXPERIMENTAL): Participants will receive oral GDC-8264, 75 mg, PO, QD for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).